BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Brainstorm Cell Therapeutics Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 17, 2026 | 0.9600 | 0.9980 | 0.8810 | 0.8810 | 82,506 |
| Nov 16, 2026 | 0.9502 | 0.9502 | 0.8910 | 0.9500 | 6,364 |
| Nov 13, 2026 | 0.9900 | 1.00 | 0.9700 | 0.9900 | 47,716 |
| Nov 12, 2026 | 0.9899 | 1.02 | 0.9500 | 1.00 | 53,284 |
| Nov 11, 2026 | 0.9900 | 0.9900 | 0.8757 | 0.9898 | 15,040 |
| Nov 10, 2026 | 0.9600 | 0.9850 | 0.8846 | 0.9729 | 27,312 |
| Nov 9, 2026 | 0.8750 | 0.9600 | 0.8300 | 0.9600 | 33,558 |
| Nov 6, 2026 | 0.9324 | 0.9324 | 0.8047 | 0.9000 | 5,418 |
| Nov 5, 2026 | 0.8200 | 0.9005 | 0.7000 | 0.8600 | 21,972 |
| Nov 4, 2026 | 0.8261 | 0.8261 | 0.8109 | 0.8261 | 5,699 |
| Nov 3, 2026 | 0.8257 | 0.8500 | 0.8257 | 0.8500 | 12,206 |
| Nov 2, 2026 | 0.8282 | 0.9570 | 0.8257 | 0.9570 | 5,422 |
| Oct 30, 2026 | 0.8703 | 0.9430 | 0.8500 | 0.8601 | 6,560 |
| Oct 29, 2026 | 0.7999 | 0.9431 | 0.7998 | 0.9087 | 78,591 |
| Oct 28, 2026 | 0.7526 | 0.7998 | 0.7526 | 0.7998 | 4,721 |
| Oct 27, 2026 | 0.8000 | 0.8000 | 0.7527 | 0.7999 | 2,566 |
| Oct 26, 2026 | 0.7882 | 0.8031 | 0.7650 | 0.7722 | 6,538 |
| Oct 23, 2026 | 0.7999 | 0.8336 | 0.7526 | 0.8219 | 28,861 |
| Oct 22, 2026 | 0.7518 | 0.8349 | 0.7518 | 0.7760 | 11,513 |
| Oct 21, 2026 | 0.7517 | 0.8344 | 0.7517 | 0.7700 | 3,196 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Executive Chairman | Grant/Award | 900.0K | -- | Jul 24, 2026 | |
| Director | Grant/Award | 100.0K | -- | Jul 24, 2026 | |
| See Remarks | Grant/Award | 100.0K | -- | Feb 26, 2026 | |
| Director | Grant/Award | 200.0K | -- | Feb 26, 2026 | |
| President & CEO | Grant/Award | 1.80M | -- | Feb 26, 2026 | |
| EVP & Chief Business Officer | Grant/Award | 150.0K | -- | Feb 26, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Lebovits Chaim President & CEO | 2.0M | 14.0% | FORM 4 |
Armistice Capital, LLC · filed May 2025 | 717.5K | 5.0% | 13G |
FRENKEL JACOB A Director | 343.8K | 2.4% | FORM 4 |
Matthew J. Ruck · may incl. warrants· stale · filed Nov 2024 | 275.8K | 1.9% | 13G |
Yablonka Uri EVP & Chief Business Officer, Director | 218.5K | 1.5% | FORM 4 |
Kevin D. Ness · may incl. warrants· stale · filed Feb 2024 | 204.0K | 1.4% | 13G |
ARBEL IRIT Director | 161.1K | 1.1% | FORM 4 |
Patlis Alla See Remarks | 144.3K | 1.0% | FORM 4 |
Dagher Ibrahim B. Chief Medical Officer | 66.8K | 0.5% | FORM 4 |
HARTOUNIAN HARTOUN EVP, Chief Operating Officer | 52.0K | 0.4% | FORM 4 |
Insiders
- Pitts Peter JoeExecutive Chairman
- FRENKEL JACOB ADirector
- Patlis AllaSee Remarks
- Lebovits ChaimPresident & CEO
- Yablonka UriEVP & Chief Business Officer
- ARBEL IRITDirector
- Lindborg StacyDirector
- Naor NirDirector
- HARTOUNIAN HARTOUNEVP, Chief Operating Officer
- Bairu MenghisteabDirector
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform. This platform employs sophisticated cell culture techniques to prompt mesenchymal stem cells, derived from the patient's own bone marrow, to produce high concentrations of neurotrophic factors. This process aims to regulate neuroinflammatory and neurodegenerative disease mechanisms, bolster the survival of neurons, and ultimately enhance neurological function. NurOwn is currently undergoing significant clinical development, having completed a Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS).
Additionally, it has successfully advanced through Phase II clinical trials for both progressive multiple sclerosis and Alzheimer's disease, with potential applications being explored for other neurodegenerative conditions. To support its therapeutic pipeline, the company has established a manufacturing partnership with Catalent for NurOwn. Incorporated in 2000, the company initially operated as Golden Hand Resources Inc. before adopting the name Brainstorm Cell Therapeutics Inc. in November 2004.
Its corporate headquarters are situated in New York, New York.
No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.
30d Avg
22.00K
60d Avg
16.54K
90d Avg
18.56K
Signal8's dilution snapshot of BCLI as of Sep 30, 2026 records an effective S-3 shelf registration (effective Sep 27, 2024), an at-the-market sales agreement dated Aug 9, 2021, 7 outstanding warrant series and a PIPE closed Oct 27, 2026, from SEC filings. Brainstorm Cell Therapeutics Inc. (OTC: BCLI) traded at $0.8810 on Nov 17, 2026, down 7.26% from the previous close of $0.9500. 52-week range: $0.4589 to $1.69. The company is in the Healthcare sector (Biotechnology).